SCLC is maybe about the worst cancer to get, life expectancy is usually very short months in most cases even with treatment which can be invasive operations and chemotherapy with terrible side effects, there is no cure available. Aztrezenica s presentation on AZD4066 indicates they are probably going to create a new trial arm to tackle this monster. Considering all the cancers they are allready targeting in the current phase1/2 trial one must conclude this AZD4066 must be something else. Also we must accept Aztrezenica will have much more data as yet not shared, exciting times for little partner Starpharma imo
SPL Price at posting:
50.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)